Design and Fabrication of 3d-printed Capsules for Enhanced Bioavailability of Dronedarone Hydrochloride with Omega-3 Fatty Acids
The aim of this study is to develop and 3D print a capsule containing dronedarone hydrochloride as the primary active ingredient in a polymer filament and omega-3 fatty acid powder as an excipient. The research hypothesis is that the bioavailability of dronedarone hydrochloride is increased by the p...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AIDIC Servizi S.r.l.
2025-07-01
|
| Series: | Chemical Engineering Transactions |
| Online Access: | https://www.cetjournal.it/index.php/cet/article/view/15449 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The aim of this study is to develop and 3D print a capsule containing dronedarone hydrochloride as the primary active ingredient in a polymer filament and omega-3 fatty acid powder as an excipient. The research hypothesis is that the bioavailability of dronedarone hydrochloride is increased by the presence of omega-3 fatty acids. A capsule was formulated and evaluated that allows the simultaneous administration of dronedarone hydrochloride and omega-3 fatty acids. Prior to the 3D printing process, a 3D capsule model was developed using CAD software. Filaments were then extruded with two formulations containing 10 % and 15 % dronedarone. The capsules were then filled with omega-3 fatty acid powder and the in vitro release of dronedarone was tested. Capsules with and without omega-3 fatty acids were tested. The release profiles of dronedarone were compared and the differences were quantified using difference and similarity factors.
The results showed that the samples with omega-3 fatty acids had a faster in vitro release of dronedarone than the samples without this excipient. In addition, a faster release was observed in samples with a higher dronedarone content in the filament, which can be attributed to an increased driving force. The difference and similarity factors showed a statistically significant difference in the release profiles of dronedarone from capsules with omega-3 fatty acids compared to capsules without this excipient. |
|---|---|
| ISSN: | 2283-9216 |